Search Results | Cancer Research | American Association for Cancer Research

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Abstract 3904: Pharmacokinetic modeling of serum platinum reveals extent of long-term exposure and associated comorbidities after cisplatin treatment

Matthew R. Trendowski, Omar El-Charif, Zepeng Mu, Mark J. Ratain, Heather Wheeler, Paul C. Dinh, Darren R. Feldman, Shirin Ardeshir-Rouhani-Fard, Robert J. Hamilton, David J. Vaughn, Chunkit Fung, Taisei Mushiroda, Lawrence H. Einhorn, Lois B. Travis, M. Eileen Dolan

Cancer Res (2019) 79 (13_Supplement): 3904.

DOI: https://doi.org/10.1158/1538-7445.AM2019-3904

Published: 01 July 2019

View article

Journal Articles

Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance)

Cancer Res (2016) 76 (14_Supplement): 2037.

DOI: https://doi.org/10.1158/1538-7445.AM2016-2037

Published: 15 July 2016

View article

Journal Articles

Abstract 3841: Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE)

Jai N. Patel, Chen Jiang, Daniel L. Hertz, Flora A. Mulkey, Paula N. Friedman, Susan Halabi, Mark J. Ratain, Michael J. Morris, Eric J. Small, Kouros Owzar, William K. Kelly, Howard L. McLeod

Cancer Res (2014) 74 (19_Supplement): 3841.

DOI: https://doi.org/10.1158/1538-7445.AM2014-3841

Published: 01 October 2014

View article

Journal Articles

Why RECIST Works and Why It Should Stay—Reply to Counterpoint

Manish R. Sharma, Michael L. Maitland, Mark J. Ratain

Cancer Res (2012) 72 (20): 5158.

DOI: https://doi.org/10.1158/0008-5472.CAN-12-1988

Published: 14 October 2012

View article

Journal Articles

RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox—Point

Manish R. Sharma, Michael L. Maitland, Mark J. Ratain

Cancer Res (2012) 72 (20): 5145–5149.

DOI: https://doi.org/10.1158/0008-5472.CAN-12-0058

Published: 14 October 2012

View article

Journal Articles

Abstract 1881: Integration of cell line and Cancer and Leukemia Group B 40101 clinical trial genome-wide association analyses implicates multiple loci in paclitaxel-induced peripheral neuropathy

Heather E. Wheeler, Eric R. Gamazon, Uchenna O. Njiaju, Claudia Wing, Chidiamara Njoku, R. Michael Baldwin, Kouros Owzar, Eric Winer, Clifford Hudis, Lawrence N. Shulman, Mark J. Ratain, Deanna L. Kroetz, Nancy J. Cox, M. Eileen Dolan

Cancer Res (2012) 72 (8_Supplement): 1881.

DOI: https://doi.org/10.1158/1538-7445.AM2012-1881

Published: 15 April 2012

View article

Journal Articles

Abstract 4717: Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies

Rebecca A. Moss, John G. Bothos, Premal H. Patel, Amy C. Peterson, Steve Eppler, Shuang Bai, Ihsan Nijem, Luc Desnoyers, Surinder Kaur, Jiping Zha, Wei Yu, Joe Simpson, Mark J. Ratain, Antoinette R. Tan, Mark N. Stein, Janice M. Mehnert, Ravi Salgia

Cancer Res (2011) 71 (8_Supplement): 4717.

DOI: https://doi.org/10.1158/1538-7445.AM2011-4717

Published: 15 April 2011

View article

Journal Articles

Functional EGFR Germline Polymorphisms May Confer Risk for EGFR Somatic Mutations in Non–Small Cell Lung Cancer, with a Predominant Effect on Exon 19 Microdeletions

Wanqing Liu, Lijun He, Jacqueline Ramírez, Soundararajan Krishnaswamy, Rajani Kanteti, Yi-Ching Wang, Ravi Salgia, Mark J. Ratain

Cancer Res (2011) 71 (7): 2423–2427.

DOI: https://doi.org/10.1158/0008-5472.CAN-10-2689

Published: 31 March 2011

View article

Includes: Supplementary data

Journal Articles

Abstract 2774: Complete results from a phase Ia dose-escalation and dose-expansion study of single-agent MetMAb, a monovalent antagonist antibody to the receptor MET, administered intravenously in patients with locally advanced or metastatic solid tumors

Ravi Salgia, Amy C. Peterson, John Bothos, Steve Eppler, Wei Yu, Priti Hegde, Bob Yauch, Jiping Zha, Mark J. Ratain, David Geary, Elayne Wesolowsky, Marjorie LaRosiliere, Premal Patel, Rebecca Moss

Cancer Res (2010) 70 (8_Supplement): 2774.

DOI: https://doi.org/10.1158/1538-7445.AM10-2774

Published: 15 April 2010

View article

Journal Articles

Abstract 2608: An intronic polymorphism determines TGF-alpha expression and is associated with cellular resistance to erlotinib

Liu Wanqing, Mark J. Ratain

Cancer Res (2010) 70 (8_Supplement): 2608.

DOI: https://doi.org/10.1158/1538-7445.AM10-2608

Published: 15 April 2010

View article

Journal Articles

Genome-wide screen for DNA copy number changes correlated with cytotoxicity to EGFR-targeted anticancer agents

Wei Zhang, Xiaolin Wu, Wanqing Liu, M. Eileen Dolan, Mark J. Ratain

Cancer Res (2006) 66 (8_Supplement): 797–798.

Published: 15 April 2006

View article

Journal Articles

Sensitivity and resistance of EGFR inhibitors in the NCI60 cell lines: Effects of both germline polymorphisms and somatic mutations

Wanqing Liu, Xiaolin Wu, Wei Zhang, Raquel C. Montenegro, Donna L. Fackenthal, Jared A. Spitz, Federico Innocenti, Soma Das, Edwin H. Cook, Jr., Nancy Cox, Mark J. Ratain

Cancer Res (2006) 66 (8_Supplement): 736.

Published: 15 April 2006

View article

Journal Articles

A Functional Common Polymorphism in a Sp1 Recognition Site of the Epidermal Growth Factor Receptor Gene Promoter

Wanqing Liu, Federico Innocenti, Michael H. Wu, Apurva A. Desai, M. Eileen Dolan, Edwin H. Cook, Jr., Mark J. Ratain

Cancer Res (2005) 65 (1): 46–53.

DOI: https://doi.org/10.1158/0008-5472.46.65.1

Published: 21 January 2005

View article

Journal Articles

Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity

M. Eileen Dolan, Karla G. Newbold, Ramamoorthy Nagasubramanian, Xiaolin Wu, Mark J. Ratain, Edwin H. Cook, Jr., Judith A. Badner

Cancer Res (2004) 64 (12): 4353–4356.

DOI: https://doi.org/10.1158/0008-5472.CAN-04-0340

Published: 17 June 2004

View article

Journal Articles

Two SNPs in the epidermal growth factor receptor (EGFR) gene promoter are associated with gene expression in vitro.

Wanqing Liu, Federico Innocenti, Michael H. Wu, Apurva Desai, M. Eileen Dolan, Edwin H. Cook, Jr., Mark J. Ratain

Cancer Res (2004) 64 (7_Supplement): 483.

Published: 01 April 2004

View article

Journal Articles

Pharmacokinetic Modulation of Irinotecan and Metabolites by Cyclosporin A

Elora Gupta, Ahmad R. Safa, Xiaolin Wang, Mark J. Ratain

Cancer Res (1996) 56 (6): 1309–1314.

Published: 01 March 1996

View article

Journal Articles

Metabolic Fate of Irinotecan in Humans: Correlation of Glucuronidation with Diarrhea

Elora Gupta, Timothy M. Lestingi, Rosemarie Mick, Jacqueline Ramirez, Everett E. Vokes, Mark J. Ratain

Cancer Res (1994) 54 (14): 3723–3725.

Published: 01 July 1994

View article

Journal Articles

Phase I and Pharmacokinetic Study of a New Antineoplastic Agent: Pyrazine Diazohydroxide (NSC 361456)

Nicholas J. Vogelzang, Rosemarie Mick, Linda Janisch, Frances Berezin, Richard L. Schilsky, Mark J. Ratain

Cancer Res (1994) 54 (1): 114–119.

Published: 01 January 1994

View article

Journal Articles

Phase I Study of Amonafide Dosing Based on Acetylator Phenotype

Mark J. Ratain, Rosemarie Mick, Frances Berezin, Linda Janisch, Richard L. Schilsky, Nicholas J. Vogelzang, L. Brian Lane

Cancer Res (1993) 53 (10): 2304–2308.

Published: 01 May 1993

View article

Journal Articles

Phase I Clinical and Pharmacological Study of Iododeoxyuridine and Bleomycin in Patients with Advanced Cancer

Richard L. Schilsky, Linda Janisch, Frances Berezin, Rosemarie Mick, Nicholas J. Vogelzang, Mark J. Ratain

Cancer Res (1993) 53 (6): 1293–1296.

Published: 01 March 1993

View article

NARROW

Abstract 3904: Pharmacokinetic modeling of serum platinum reveals extent of long-term exposure and associated comorbidities after cisplatin treatment

Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance)

Abstract 3841: Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE)

Why RECIST Works and Why It Should Stay—Reply to Counterpoint

RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox—Point

Abstract 1881: Integration of cell line and Cancer and Leukemia Group B 40101 clinical trial genome-wide association analyses implicates multiple loci in paclitaxel-induced peripheral neuropathy

Abstract 4717: Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies

Functional EGFR Germline Polymorphisms May Confer Risk for EGFR Somatic Mutations in Non–Small Cell Lung Cancer, with a Predominant Effect on Exon 19 Microdeletions

Abstract 2774: Complete results from a phase Ia dose-escalation and dose-expansion study of single-agent MetMAb, a monovalent antagonist antibody to the receptor MET, administered intravenously in patients with locally advanced or metastatic solid tumors

Abstract 2608: An intronic polymorphism determines TGF-alpha expression and is associated with cellular resistance to erlotinib

Genome-wide screen for DNA copy number changes correlated with cytotoxicity to EGFR-targeted anticancer agents

Sensitivity and resistance of EGFR inhibitors in the NCI60 cell lines: Effects of both germline polymorphisms and somatic mutations

A Functional Common Polymorphism in a Sp1 Recognition Site of the Epidermal Growth Factor Receptor Gene Promoter

Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity

Two SNPs in the epidermal growth factor receptor (EGFR) gene promoter are associated with gene expression in vitro.

Pharmacokinetic Modulation of Irinotecan and Metabolites by Cyclosporin A

Metabolic Fate of Irinotecan in Humans: Correlation of Glucuronidation with Diarrhea

Phase I and Pharmacokinetic Study of a New Antineoplastic Agent: Pyrazine Diazohydroxide (NSC 361456)

Phase I Study of Amonafide Dosing Based on Acetylator Phenotype

Phase I Clinical and Pharmacological Study of Iododeoxyuridine and Bleomycin in Patients with Advanced Cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only